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Serial tneasuretnents of circulating tissue plastninogen
activator and fibrin(ogen) degradation products predict
outcotne in gestational proteinuric hypertension
C. A. DEJAGER, s. c. ROBSON, R. E. KIRSCH, P.JACOBS, C. HARVEST,
T. DUNNE, J. ANTHONY
Abstract Gestational proteinuric hypertension (GPH), a
IIlajor cause of IIlaternal death, IIlay be charac-
terised by hypertension and proteinuria alone or
IIlay progress to disturbed coagulation and IIlulti-
organ failure. Since the condition can only be
reversed by terInination of pregnancy, there is a
need for reliable indicators of severity. We found
circulating levels of tissue plasIninogen activator
(tPA)(27,98 ± 2,12 v. 7,17 ± 0,81 ng/Inl, IIlean ±
SEM), fibrin(ogen) degradation products (FDP)
(7,55 ± 1,99 v. 1,92 ± 0,47 IlglInl) and fibronectin
(221 ± 15,2 v. 120 ± 15,2 IlglInl) to be significantly
increased in 21 patients with severe GPH when
cOIIlpared with 21 nOrIIlotensive, age- and gesta-
tional age-IIlatched pregnant controls. More
iInportantly, patients who developed severe GPH
showed a progressive increase in tPA and FDP
levels with tiIIle. This was in contrast to patients
who had hypertension and proteinuria alone, in
WhOIIl tPA and FDP concentrations did not
increase. Parallel IIleasureIIlents did not reveal a
fall in platelet count or an increase in urinary
protein excretion in patients who subsequently
progressed to severe disease. Our findings IIlay be
of assistance to clinicians faced with the need to
prolong pregnancy in patients with GPH in order
to ensure fetal viability.
S Air Med J 1993; 83: 898-899.
G estational proteinuric hypertension (GPH) is amajor cause of maternal death in the Westernworld. I Patients may present with hypertension
and proteinuria alone or may develop fulminant disease
with disturbed coagulation, vascular injury and multi-
system failure. 2,3 The reason for this progression is
unclear and there are currently no early clinical or labo-
ratory predictors of severity that are generally accept-
able.
We evaluated plasma and serum concentrations of
tissue plasminogen activator (tPA) and fibrin(ogen)
degradation products (FDP) prospectively in patients
with GPH and present data suggesting that the rate of
increase oftPA and FDP in the circulation may assist in
predicting the outcome in such patients.
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Patients and methods
The study was conducted in rwo phases. In the first
phase, circulating tPA, FDP and fibronectin (Fn) con-
centrations were measured in 21 consecutive patients
with severe progressive (fulminant) GPH and 21 healthy,
normotensive pregnant women matched for age, race,
gestational age and parity. All control patients remained
normotensive throughout pregnancy and the puerperi-
um. In the second phase 22 consecutive patients with
GPH admitted to the Groote Schuur Hospital region
underwent twice weekly estimations of full blood count,
platelet count, 24-hour urinary protein excretion, cir-
culating tPA, FDP and Fn concentrations from the time
of presentation to the time of delivery. Eleven of these
patients progressed to severe maternal disease, while the
remainder were delivered for fetal indications. All
patients and control subjects were examined and fol-
lowed up by one physician (J.A.) who was responsible
for defining and recording the outcome without know-
ledge of the trial data. GPH was considered to be pre-
sent in any patient with a blood pressure of 140/90
mmHg or more who had a 24-hour urinary protein
excretion in excess of 0,3 g. Any patient with a sustained
blood pressure greater than or equal to 160/110 mmHg
or a platelet count of less than 150 x 109/1 or a count
that fell by more than 50 x 109/1 over a period of 3 days
or with organ dysfunction ascribed to GPH was con-
sidered to have severe or progressive disease!
The protocol was approved by the Ethics and
Research Committee of the University of Cape Town.
All patients were fully informed and agreed to have part
of routinely collected blood used for this study.
Blood collection and preparation of
serum
To limit in vitro fibrinolysis, blood samples were collect-
ed in cold polystyrene tubes containing 3,8% sodium
citrate and 0,025M aminocaproic acid. Plasma was
separated within 4 hours of collection, and stored at
-70°C until analysis. Serum was prepared by clorting
the plasma in a IIlixtwe containing thrombin and soy-
bean trypsin inhibitor for 4 hours at ooe, as recom-
mended by Merskey et al.'
Laboratory investigations
Fibrin(ogen) degradation products were determined in
serum by an enzyme-linked immunoassay (ELISA)
developed in our laboratory.6 Tissue plasminogen acti-
vator was measured in plasma using the Imubind-5-tPA
ELISA kit (American Diagnostica Inc., Greenwich,
Corm., USA).7 Fn concentrations in serum were mea-
sured by means of EUSA with polyclonal rabbit anti-
human Fn IgG as capturing antibody, mouse anti-
human Fn monoclonal antibody, CJ2, raised in our
laboratory, and goat antimouse immunoglobulin conju-
gated to peroxidase.
Statistical methods
In phase 1 of the study mean values for each group were
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the amount of proteinuria, the platelet count and tests
of renal and hepatic function, all of which are relatively
late signs of progression.
Since endothelial damage is thought to occur at an
early stage," we have examined markers of such injury in
the hope that these may prove to be useful indicators of
severity.
The results of phase 1 of this study confirm previous
work suggesting that Fn concentrations are significantly
higher in pregnancies complicated by GPH.. The find-
ing that serum FDP and plasma IPA concentrations are
increased lends additional suppon to the contention
that endothelial damage, disordered coagulation and
fibrinolysis play a central role in the pathogenesis of this
condition.
Of imponance is our interpretation of the estimated
rates of change of serum FDP and plasma IPA. When
FDP rates of change greater than 2,50 ~ml/wk are sus-
tained in the same individual after several observations,
there is an increased probability of progression to severe
disease. This increased probability also holds for sus-
tained tPA rates of change of 2,20 ng/ml or more per
week. However, these increased probabilities are not so
marked as to be in any sense clinically definitive.
Similarly, sustained rates of change below the stated
FDP and IPA rates will be associated with decreased
probability of progression and, in the absence of other
indications, suggest that pregnancy may not need to be
terminated. Our finding that neither a fall in platelet
count nor an increase in degree of proteinuria reliably
predict progression to severe disease funher emphasises
the possible imponance of the above conclusions. The
observation that both FDP and IPA rates of change are
of the requisite order in the same patient is reassuring.
Since these criteria represent different components of
the same process, the use of both criteria only margi-
nally increases the predictive power of one criterion
alone. While the rate of increase ofFDP and IPA should
clearly not be considered in isolation, we believe that
these measurements will provide a valuable additional
prognostic index. Our data indicate that GPH is un-
likely to progress in patients with static levels of FDP
and IPA and suggest that pregnancy be maintained in






7,55 ± 1,99* 27,98 ± 2,12* 221 ± 15,2*
compared by means of Student's [-test. Non-parametric
distribution-free tests were used to confirm the existence
of differences between groups. In phase 2, multiple
observations allowed parallel linear regressions (different
intercepts but common slope and common variance) to
detect linear changes in some responses with regard to
increasing gestational age.
In the sequential study, data were analysed according
to gestational age, from admission through to delivery.
Control data gave no evidence of any linear regression
of serum FDP, Fn or IPA levels with gestational age. A
common slope and variance model was fitted within
each of the two GPH groups. This fitting revealed a
marked relationship between serum FDP concentration
and gestational age in patients with severe, progressive
GPH. This relationship amounted to a change of 12,38
± 4,40 IJg FDP/ml serum/wk (P = 0,007). In contrast,
there was no relationship between FDP concentration
and gestational age in patients who had hypenension
and proteinuria alone (0,09 ± 1,07 Ilg FDP/ml
serum/wk; P= 0,935).
Analysis of the tPA-gestational age relationship
revealed similar changes - 6,82 ± 2,17 ng IPNml plas-
ma/wk; (P =0,003) in severe disease and 1,02 ± 0,53 ng
tPNml plasma/wk (P =0,059) in the patients with
hypenension and proteinuria alone.
There was no relationship between serum Fn con-
centration and gestational age in either group of patient
data. Parallel measurements did not reveal a fall in
platelet counts or an increase in urinary protein excre-
tion in those patients who subsequently progressed to
severe disease.
The concentrations of FDP (mean ± SEM) (7,55 ±
1,99 v. 1,92 ± 0,47 ~ml; P = 0,008), IPA (27,98 ±
2,12 v. 7,17 ± 0,81 ng/ml; P < 0,0001) and Fn (221 ±
15,2 v. 120 ± 15,2 ~ml; P < 0,0001) were significantly
higher in patients with gestational proteinuric hypenen-





Fulminant GPH is a progressive disorder reversed only
by termination of pregnancy. The high maternal mor-
bidity and occasional monality associated with severe
forms of this condition are an absolute indication for
immediate delivery. Prolongation of the pregnancy
beyond 28 - 32 weeks' gestational age may benefit the
fetus and is the goal of management in milder cases
where the condition is characterised by hypenension
and proteinuria alone. Unfonunately, the course of the
disease is often unpredictable and physicians are forced
to rely on the degree or rate of increase of hypenension,
